The Food and Drug Administration Modernization Act and the Food and Drug Administration: Metamorphosis or Makeover?

被引:0
|
作者
Christopher-Paul Milne
机构
[1] Tufts University,Tufts Center for the Study of Drug Development
来源
Drug information journal : DIJ / Drug Information Association | 2000年 / 34卷 / 3期
关键词
FDA Modernization Act; FDAMA; Food and Drug Administration; Rule making;
D O I
暂无
中图分类号
学科分类号
摘要
The Food and Drug Administration Modernization Act of 1997 (FDAMA) is the first legislation to bring about significant and widespread modifications to the regulatory environment for drugs and biologicals in more than 35 years. The expectations of what FDAMA is to accomplish are high. This article reviews the results from the first two years of implementation of the major FDAMA provisions for drugs and biologicals. First, however, the elements of the adversarial culture that brought about the impetus to modernize FDA are discussed. Next the article focuses on FDA’s more “modernized” approach to the process of governing, through the use of such mechanisms as governance by guidance, direct final rules, national videoconferences, and stakeholders meetings. In addition, the process for implementing FDAMA and what the products of that process have been, both the rules themselves and the outcomes for the regulated community, are discussed. Lastly, the article considers whether FDA is capable of change and what the real message of FDAMA is.
引用
收藏
页码:681 / 692
页数:11
相关论文
共 50 条
  • [21] Sam Greenhouse: his contributions as a consultant to the Food and Drug Administration
    O'Neill, RT
    STATISTICS IN MEDICINE, 2003, 22 (21) : 3285 - 3289
  • [22] Food and Drug Administration Evaluation and Cigarette Smoking Risk Perceptions
    Kaufman, Annette R.
    Waters, Erika A.
    Parascandola, Mark
    Augustson, Erik M.
    Bansal-Travers, Maansi
    Hyland, Andrew
    Cummings, K. Michael
    AMERICAN JOURNAL OF HEALTH BEHAVIOR, 2011, 35 (06): : 766 - 776
  • [23] Texas pharmacists' knowledge of reporting serious adverse drug events to the Food and Drug Administration
    Gavaza, Paul
    Brown, Carolyn M.
    Lawson, Kenneth A.
    Rascati, Karen L.
    Wilson, James P.
    Steinhardt, Mary
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2011, 51 (03) : 397 - U135
  • [24] The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers
    Karas, Laura
    Lu, Christine Y.
    Agrawal, Pankaj B.
    Asgari, Maryam M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (03) : 867 - 877
  • [25] The Nutrition Facts Label - U.S. Food and Drug Administration
    Beckwell, Jillian
    JOURNAL OF CONSUMER HEALTH ON THE INTERNET, 2025, 29 (01) : 86 - 100
  • [27] Food and drug administration approval process for dermatology drugs in the United States
    Boozalis, Emily
    Semenov, Yevgeniy R.
    Kwatra, Shawn G.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 (06) : 536 - 538
  • [28] The Food and Drug Administration and pragmatic clinical trials of marketed medical products
    Anderson, Monique L.
    Griffin, Joseph
    Goldkind, Sara F.
    Zeitler, Emily P.
    Wing, Liz
    Al-Khatib, Sana M.
    Sherman, Rachel E.
    CLINICAL TRIALS, 2015, 12 (05) : 511 - 519
  • [29] Black box 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk
    Murphy, S
    Roberts, R
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (01) : 34 - 39
  • [30] Review of red yeast rice content and current Food and Drug Administration oversight
    Childress, Lindsey
    Gay, Andrea
    Zargar, Atanaz
    Ito, Matthew K.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2013, 7 (02) : 117 - 122